Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,389,627 papers from all fields of science
Search
Sign In
Create Free Account
Isocarboxazid
Known as:
Isocarboxazid [Chemical/Ingredient]
, Isocarboxazide
, 3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide
Expand
A hydralazine and monoamine oxidase (MAO) inhibitor with antidepressant activity. Isocarboxazid blocks the breakdown (oxidative deamination) of…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
19 relations
Broader (2)
Antidepressive Agents
Monoamine Oxidase Inhibitors
Cerebrovascular Disorders
Depressive disorder
Drug Allergy
Hypertensive disease
Expand
Narrower (2)
Isocarboxazid Oral Tablet [Marplan]
Marplan
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression
K. Shulman
,
N. Herrmann
,
S. Walker
CNS Drugs
2013
Corpus ID: 21625538
This paper reviews the discovery and history of the use of irreversible monoamine oxidase (MAO) inhibitors (MAOIs) such as…
Expand
Highly Cited
1998
Highly Cited
1998
Listening to Prozac but Hearing Placebo: A Meta-Analysis of Antidepressant Medication
I. Kirsch
,
Guy Sapirstein
1998
Corpus ID: 11855011
Mean effect sizes for changes in depression were calculated for 2,318 patients who had been randomly assigned to either…
Expand
Review
1995
Review
1995
MAOIs in the Contemporary Treatment of Depression
M. Thase
,
M. Trivedi
,
A. Rush
Neuropsychopharmacology
1995
Corpus ID: 6271478
1991
1991
Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression
J. K. Larsen
,
A. Gjerris
,
+13 authors
O. Rafaelsen
Acta Psychiatrica Scandinavica
1991
Corpus ID: 6392167
Moclobemide was compared with isocarboxazide and clomipramine in patients with depression. A total of 167 outpatients were…
Expand
Highly Cited
1988
Highly Cited
1988
A trial of isocarboxazid in the treatment of bulimia nervosa.
Sidney H. Kennedy
,
N. Piran
,
+4 authors
Paul E. Garfinkel
Journal of Clinical Psychopharmacology
1988
Corpus ID: 6773039
Eighteen women completed a double-blind, placebo-controlled crossover study designed to investigate the effects of isocarboxazid…
Expand
Highly Cited
1988
Highly Cited
1988
An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.
Jonathan R. T. Davidson
,
Earl L. Giller
,
Sidney Zisook
,
John E. Overall
Archives of General Psychiatry
1988
Corpus ID: 9188477
Isocarboxazid and placebo were evaluated in 130 anxious depressives. Drug was superior to placebo on depression, anxiety…
Expand
Highly Cited
1968
Highly Cited
1968
DNA damage caused by antidepressant hydrazines and related drugs.
E. Freese
,
S. Sklarow
,
E. Freese
Mutation research
1968
Corpus ID: 42819147
Highly Cited
1966
Highly Cited
1966
An electrophysiological study of 5‐hydroxytryptamine receptors of neurones in the molluscan nervous system
H. Gerschenfeld
,
E. Stefani
Journal of Physiology
1966
Corpus ID: 26098335
1. 5‐Hydroxytryptamine (5‐HT) has been iontophoretically applied to the membrane of central neurones of Cryptomphallus aspersa…
Expand
1963
1963
Reserpine, monoamine oxidase inhibitors, and distribution of biogenic amines in monkey brain.
G. Pscheidt
,
H. Himwich
Biochemical Pharmacology
1963
Corpus ID: 42806969
Highly Cited
1962
Highly Cited
1962
Drug therapy in depressions: Controlled evaluation of imipramine, isocarboxazide, dextroamphetamine‐amobarbital, and placebo
J. Overall
,
L. Hollister
,
A. Pokorny
,
J. F. Casey
,
G. Katz
Clinical pharmacology and therapy
1962
Corpus ID: 27190170
An evaluation of imipramine, isocarboxazide, dextroamphetamine‐amobarbital, and placebo was carried out in 204 patients with…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE